top
Search terms
Results 1 - 2 of 2 - ordered by :
Escardio

The off-label use of sildenafil in the treatment of residual hypertension in patients with valvular heart disease leads to worse clinical outcomes including a doubled risk of hospitalisation compared ...

Date : 29/08/2017
Escardio

Over a median follow-up of 18.2 months, the primary outcome occurred in 386 of 2,373 patients (16.3%) in the dapagliflozin group and in 502 of 2,371 patients (21.2%) in the placebo group (hazard ...

Date : 01/09/2019